Prognostic value of hypoxia-inducible factor-1 alpha and prolyl 4-hydroxylase beta polypeptide overexpression in gastric cancer

Table 2 Hypoxia-inducible factor-1α and prolyl 4-hydroxylase beta expressions and clinicopathologic characteristics

Characteristics	HIF-1α				P4HB
	Low	High	P value	χ2	Low	High	P value	χ2
	209 (48.8)	219 (51.2)			213 (49.8)	215 (50.2)
Age			0.42	0.65			0.35	0.57
< 60	93 (46.7)	106 (53.3)			96 (48.2)	103 (51.8)
≥ 60	116 (50.7)	113 (49.3)			117 (51.1)	112 (48.9)
Gender			0.91	0.01			0.48	0.49
Male	149 (49.0)	155 (51.0)			148 (48.7)	156 (51.3)
Female	60 (48.4)	64 (51.6)			65 (52.4)	59 (47.6)
Bormann type			0.06	7.26			0.00	29.18
I	16 (48.5)	17 (51.5)			26 (78.8)	7 (21.2)
II	104 (55.0)	85 (45.0)			110 (58.2)	79 (41.8)
III	88 (44.0)	112 (56.0)			75 (37.5)	125 (62.5)
V	1 (16.7)	5 (83.3)			2 (33.3)	4 (66.7)
Tumor size			0.30	1.09			0.00	11.09
< 5 cm	124 (51.0)	119 (49.0)			138 (42.0)	110 (58.0)
≥ 5 cm	85 (45.9)	100 (54.1)			75 (14.6)	105 (85.4)
Tumor histological morphology			0.18	3.45			0.49	1.42
Adenocarcinoma	157 (49.2)	162 (50.8)			163 (51.1)	156 (48.9)
Absolute signet ring cell carcinoma	3 (100.0)	0 (0.0)			2 (66.7)	1 (33.3)
Mixed carcinoma	49 (46.2)	57 (53.8)			48 (45.3)	58 (54.7)
Location			0.15	3.78			0.63	0.94
Up	40 (14.4)	50 (55.6)			41 (45.6)	49 (54.4)
Middle	53 (43.8)	68 (56.2)			60 (49.6)	61 (50.4)
Low	116 (53.5)	101 (46.5)			112 (51.6)	105 (48.4)
Lauren type			0.05	5.98			0.57	1.14
Intestinal	96 (48.0)	104 (52.0)			104 (52.0)	96 (48.0)
Diffuse	73 (56.6)	56 (43.4)			64 (49.6)	65 (50.4)
Mixed type	40 (40.4)	59 (59.6)			45 (45.5)	54 (54.5)
Tumor differentiation			0.08	3.17			0.03	4.53
Poor	132 (45.8)	156 (54.2)			133 (46.2)	155 (53.8)
Moderate and high	77 (55.0)	63 (45.0)			80 (57.1)	60 (42.9)
Vessel invasion			0.21	1.60			0.38	0.78
No	152 (50.8)	147 (49.2)			153 (51.2)	146 (48.8)
Yes	57 (44.2)	72 (55.8)			60 (46.5)	69 (53.5)
Perineural invasion			0.41	0.69			0.03	4.71
No	160 (50.0)	160 (50.0)			169 (52.8)	151 (47.2)
Yes	49 (45.4)	59 (54.6)			44 (40.7)	92 (59.3)
T category			0.01	10.93			0.00	44.94
T1	32 (88.9)	4 (11.1)			9 (56.3)	7 (43.8)
T2	11 (45.8)	13 (54.2)			13 (54.2)	11 (45.8)
T3	41 (45.1)	50 (54.9)			69 (81.2)	16 (18.8)
T4	125 (45.1)	152 (54.9)			122 (40.3)	181 (59.7)
N category			0.00	23.55			0.00	54.13
N0	111 (62.0)	68 (38.0)			126 (70.4)	53 (29.6)
N1	28 (41.8)	39 (58.2)			28 (41.8)	39 (58.2)
N2	37 (44.0)	47 (56.0			28 (33.3)	56 (66.7)
N3	33 (33.7)	65 (66.3)			31 (31.6)	67 (68.4)
TNM stage			0.00	23.32			0.00	65.64
I	54 (58.1)	39 (41.9)			72 (77.4)	21 (22.6)
II	65 (64.4)	36 (35.6)			65 (64.4)	36 (35.6)
III	87 (38.2)	141 (61.8)			75 (32.9)	1503 (67.1)
IV	3 (50.0)	3 (50.0)			1 (16.7)	5 (83.3)
Operation			0.69	0.16			0.18	1.79
D1	2 (40.0)	3 (60.0)			1 (20.0)	4 (80.0)
D2	207 (48.9)	216 (51.1)			212 (50.1)	211 (49.9)
Hepatic metastases			0.01	6.98			0.07	3.38
Yes	14 (30.4)	32 (69.6)			17 (37.0)	29 (63.0)
No	195 (51.0)	187 (49.0)			196 (51.3)	186 (48.7)
Peritoneum cavity metastasis			0.00	12.67			0.00	39.29
Yes	58 (37.4)	97 (62.6)			46 (29.7)	109 (70.3)
No	151 (55.3)	122 (44.7)			167 (61.2)	106 (38.8)

HIF-1α: Hypoxia-inducible factor-1α; P4HB: Prolyl 4-hydroxylase beta.